Technology area: Biotechnology & Pharmaceuticals
13 pending office actions • 4 art units • 11 examiners • 0 of 13 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Caregen Co., Ltd. has 14 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 12 distinct examiners, which is a high number of individuals relative to the 4 distinct art units involved. This concentration in 4 art units suggests that while many examiners are involved, they are grouped within a limited number of specialized office divisions. The ratio of 14 pending office actions to 12 distinct examiners indicates that very few examiners are handling multiple cases for the company.
KONOPELSKI SNAVEL, SARA ELIZABETH is the busiest examiner, holding 2 pending office actions. This busiest examiner pending count of 2 is the highest concentration of work for any single examiner in this portfolio. The remaining pending office actions are spread across the other distinct examiners. Practitioners should focus on the 4 distinct art units to understand the primary administrative hurdles, even as they navigate the preferences of 12 distinct examiners. The presence of 14 pending office actions in the Biotechnology & Pharmaceuticals area represents the total volume of ongoing negotiation with the patent office. KONOPELSKI SNAVEL, SARA ELIZABETH manages a larger portion of the workload than the other examiners.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (8%) |
| §101 + other | 6 (46%) |
| Multi-statute (no §101) | 6 (46%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KONOPELSKI SNAVEL, SARA ELIZABETH | 2 | 35.0% | +35.4% |
| BEANE, RANDALL L | 2 | 32.9% | +36.2% |
| BRADLEY, CHRISTINA | 1 | 62.6% | +33.3% |
| BANERJEE, KOYELI | 1 | 33.3% | +0.0% |
| HA, JULIE | 1 | 75.7% | +44.1% |
| CARTER, SANDRA DILLAHUNT | 1 | 56.2% | +28.6% |
| BORGEEST, CHRISTINA M | 1 | 55.7% | +21.4% |
| JAUHARI, SACHI | 1 | 60.0% | +80.0% |
| HELLMAN, KRISTINA M | 1 | 65.1% | +55.5% |
| KOMATSU, LI N | 1 | 59.8% | +71.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18009452 | COMPOSITION FOR PREVENTION, IMPROVEMENT OR TREATMENT OF ALLERGIC DISEASE OR ITCHING COMPRISING PENTAPEPTIDE AS ACTIVE INGREDIENT | KOMATSU, LI N | 97d overdue |
| 18038607 | PEPTIDE HAVING PROTECTIVE ACTIVITY AGAINST CELL DAMAGE CAUSED BY PARTICULATE MATTER, AND USES FOR SAME | BEANE, RANDALL L | 4d overdue |
| 17629313 | PEPTIDE HAVING HAIR GROWTH PROMOTING ACTIVITY, AND USE THEREOF | NIEBAUER, RONALD T | 3d overdue |
| 18850815 | PEPTIDE HAVING ANTI-INFLAMMATORY AND ANTI-FIBROTIC ACTIVITIES AND USE THEREOF | BRADLEY, CHRISTINA | — |
| 18695526 | PEPTIDE HAVING ACTIVITY OF PREVENTING HAIR LOSS OR PROMOTING HAIR GROWTH AND USE THEREOF | BANERJEE, KOYELI | — |
| 18724352 | PEPTIDE HAVING ACTIVITY OF IMPROVING STATE OF SKIN, AND USE THEREOF | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| 18724295 | PEPTIDE HAVING ACTIVITY OF IMPROVING STATE OF SKIN, AND USE THEREOF | HA, JULIE | — |
| 18706716 | PEPTIDE HAVING PHYSIOLOGICAL ACTIVITY AND USE THEREOF | CARTER, SANDRA DILLAHUNT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18009452 | COMPOSITION FOR PREVENTION, IMPROVEMENT OR TREATMENT OF ALLERGIC DISEASE OR ITCHING COMPRISING PENTAPEPTIDE AS ACTIVE INGREDIENT | KOMATSU, LI N | 97d overdue |
| 18038607 | PEPTIDE HAVING PROTECTIVE ACTIVITY AGAINST CELL DAMAGE CAUSED BY PARTICULATE MATTER, AND USES FOR SAME | BEANE, RANDALL L | 4d overdue |
| 18850815 | PEPTIDE HAVING ANTI-INFLAMMATORY AND ANTI-FIBROTIC ACTIVITIES AND USE THEREOF | BRADLEY, CHRISTINA | — |
| 18724352 | PEPTIDE HAVING ACTIVITY OF IMPROVING STATE OF SKIN, AND USE THEREOF | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| 18724295 | PEPTIDE HAVING ACTIVITY OF IMPROVING STATE OF SKIN, AND USE THEREOF | HA, JULIE | — |
| 18706716 | PEPTIDE HAVING PHYSIOLOGICAL ACTIVITY AND USE THEREOF | CARTER, SANDRA DILLAHUNT | — |
| 18706717 | PEPTIDE HAVING PHYSIOLOGICAL ACTIVITIES AND USE THEREOF | BORGEEST, CHRISTINA M | — |
| 18697403 | PEPTIDE HAVING ANTI-AGING ACTIVITY, AND USE THEREOF | JAUHARI, SACHI | — |
| Art Unit | Apps |
|---|---|
| 1658 | 6 |
| 1654 | 5 |
| 1674 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18850815 | PEPTIDE HAVING ANTI-INFLAMMATORY AND ANTI-FIBROTIC ACTIVITIES AND USE THEREOF | BRADLEY, CHRISTINA | 1658 | §102§103 | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18695526 | PEPTIDE HAVING ACTIVITY OF PREVENTING HAIR LOSS OR PROMOTING HAIR GROWTH AND USE THEREOF | BANERJEE, KOYELI | 1658 | §101§102§112 | Non-Final OA | — | Pending | Aug 30, 2024 |
| 18724352 | PEPTIDE HAVING ACTIVITY OF IMPROVING STATE OF SKIN, AND USE THEREOF | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §101§112 | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18724295 | PEPTIDE HAVING ACTIVITY OF IMPROVING STATE OF SKIN, AND USE THEREOF | HA, JULIE | 1654 | §101 | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18706716 | PEPTIDE HAVING PHYSIOLOGICAL ACTIVITY AND USE THEREOF | CARTER, SANDRA DILLAHUNT | 1674 | §102§112 | Non-Final OA | — | Pending | May 01, 2024 |
| 18706717 | PEPTIDE HAVING PHYSIOLOGICAL ACTIVITIES AND USE THEREOF | BORGEEST, CHRISTINA M | 1675 | §101§102§103§112 | Non-Final OA | — | Pending | May 01, 2024 |
| 18697403 | PEPTIDE HAVING ANTI-AGING ACTIVITY, AND USE THEREOF | JAUHARI, SACHI | 1654 | §102§112 | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18697386 | PEPTIDE HAVING ANTI-AGING ACTIVITY, AND USE THEREOF | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §101§102§112 | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18695739 | PEPTIDE HAVING ANTI-INFLAMMATORY ACTIVITY AND USE THEREOF | HELLMAN, KRISTINA M | 1654 | §102§112 | Non-Final OA | — | Pending | Mar 26, 2024 |
| 18695068 | PEPTIDE HAVING ACTIVITY OF PREVENTING HAIR LOSS OR PROMOTING HAIR GROWTH, AND USE THEREOF | BEANE, RANDALL L | 1654 | §102§112Other | Non-Final OA | — | Pending | Mar 25, 2024 |
| 18038607 | PEPTIDE HAVING PROTECTIVE ACTIVITY AGAINST CELL DAMAGE CAUSED BY PARTICULATE MATTER, AND USES FOR SAME | BEANE, RANDALL L | 1654 | §101§102§112 | Non-Final OA | 4d overdue | Pending | May 24, 2023 |
| 18009452 | COMPOSITION FOR PREVENTION, IMPROVEMENT OR TREATMENT OF ALLERGIC DISEASE OR ITCHING COMPRISING PENTAPEPTIDE AS ACTIVE INGREDIENT | KOMATSU, LI N | 1658 | §102§103§112Other | Non-Final OA | 97d overdue | Pending | Dec 09, 2022 |
| 17629313 | PEPTIDE HAVING HAIR GROWTH PROMOTING ACTIVITY, AND USE THEREOF | NIEBAUER, RONALD T | 1658 | §101§112 | Final Rejection | 3d overdue | Pending | Jan 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCaregen Co., Ltd. has 13 pending office actions as of October 2026, spread across 4 art units and 11 examiners.
Sara Elizabeth Konopelski Snavel has the most, with 2 of Caregen Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
